WHY WE ARE

To empower people, medical institutions and nations to gain universal access to effective cancer diagnostic tools.

In essence, we accelerate and facilitate solutions from labs to villages.

About-Us-photo

WHO WE ARE

BioMark is an oncology focused company with advanced stage diagnostic technologies and promising anti-body based cancer treatment pipeline.

The diagnostic technology was initially licensed from the University of Manitoba in Canada.

Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.

BIOMARK TEAM

EXECUTIVE TEAM & ADVISORS

Research/Scientific/Clinical

Dr. Daniel S. Sitar – Principal Scientific Advisor/Consultant
Dr. John Yoo – Clinical Oncologist – Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario
Dr. John Schrader – Antibody development – Chair of Biomedical, Research Centre at University of British Columbia
Dr. Horacio Bach – Antibody Engineering UBC
Dr. Safieddin Safavi-Naeini – NSERC/BlackBerry Industrial Research Chair at University of Waterloo

Media Advisory Board

Bill Good – Veteran Broadcaster, Honorary Doctorate of Technology from BCIT

Regulatory

Dr. Ramjiawan from SBRC – Clinical Trial and Regulatory Expertise

Downstream

Jim Elliott – Downstream Technology Advisor and QMS support

North American Management

Rashid Ahmed – Founder, Chief Executive Officer
Dr. Thomas Malcolm – President & Chief Scientific Officer
Brian Cheng – Chief Technical Officer
Abbey Abdiye – Chief Financial Officer (Canada)
Neal Kaplan – Chief Financial Officer (US)
Dr. Kenneth Kohn – Patent Attorney
Gina Huang – Project Director

Medical Delivery Panel

Dr. James Bond – Chief of Thoracic Surgeon Surrey Hospital
Dr. Dwight De Risi – Breast Oncology Surgeon
Dr. Debra Hoffman – Lung Oncology Surgeon

Supporting

Dr. Reuven Gordon and Dr. Fraser Hof Canadian Research Chairs, Uvic
Dr. Andrew Maksymiuk University of Manitoba and Manitoba CancerCare
Dr. Samudra Dissanyake – Scientific Advisor business development
Stan Lee – Chartered Accountant

Auditor

Manning Elliott Accountants & Business Advisors

EXECUTIVE TEAM & ADVISORS

Cross Pollinated, Balanced and Committed team since 2007.

-Learn more

CANCER DIAGNOSTICS

BioMark Pushing the Limit of Early Detection.

-Learn more

AWARDS, GRANTS, RECOGNITIONS

• Genome BC in Oct 2013 – BioMark and Dr. Reuven funding for
the use of Raman IR for cancer biomarker development

-Learn more

STRATEGIC COLLABORATIONS

• Biopharmaceutical Research Inc.
• University of Manitoba

-Learn more